ABSTRACT
The effect of transtraumatic epidural electrostimulation (TEES) above (T5) and below (L2) spinal cord injury in the lower thoracic region (T8-T9) in combination with treadmill exercise in pigs was evaluated using electrophysiological examination methods and behavioral tests. Two weeks after spinal cord injury, motor evoked potentials of m. soleus were recorded during electrostimulation at the level of T5 and L2 segments, which indicated activation of spinal cord structures above and below the focus of injury. After 6 weeks of TEES in combination with physical training, restoration of the characteristics of M-response and H-reflex of the soleus muscle in response to stimulation of the sciatic nerve, improvement of joint mobility, and appearance of voluntary motor activity in the hindlimbs were observed. Neuromodulation with TEES had been proven to be an effective way to stimulate posttraumatic spinal cord regeneration and can be used in the development of a neurorehabilitation protocol for patients with spinal cord injury.
Subject(s)
Electric Stimulation Therapy , Spinal Cord Injuries , Animals , Swine , Spinal Cord/physiology , Spinal Cord Injuries/therapy , Muscle, Skeletal/physiology , Evoked Potentials, Motor/physiologyABSTRACT
Metabolism of a new neuroprotector GZK-111 (N-phenylacetylglycyl-L-proline ethyl ester) in rat blood plasma was studied by HPLC-mass spectrometry. Four biotransformation products were identified. It is concluded that the main ways of GZK-111 biotransformation are hydrolysis of the ester bond by esterases followed by degradation of the resulting metabolite, as well as reactions leading to the formation of phenylacetic acid and cycloprolylglycine that exhibits neuropsychotropic activity.
Subject(s)
Dipeptides , Neuroprotective Agents , Animals , Biotransformation , Chromatography, High Pressure Liquid , Dipeptides/pharmacology , Hydrolysis , Mass Spectrometry , Neuroprotective Agents/pharmacology , RatsABSTRACT
We studied the pharmacokinetics of GZK-111 (N-phenylacetyl-glycyl-L-proline ethyl ether), a compound with neuroprotective activity, and its metabolite CPG (cyclo-L-prolylglycine) in rat blood plasma after single intravenous and intragastric administration in a dose of 20 mg/kg. It was found that the parent drug undergoes intensive biotransformation; its metabolite CPG persists in the circulation more than twice as long as GZK-111 and its plasma concentrations were higher by 50-70 times than the concentrations of the parent compound.
Subject(s)
Dipeptides , Animals , Dipeptides/chemistry , RatsABSTRACT
INTRODUCTION: The aim of this study is to assess the influence of gene CYP2C19, CYP3A4, CYP3A5 and ABCB1 polymorphisms on clopidogrel antiplatelet activity, rivaroxaban concentration equilibrium, and clinical outcomes among patients with acute coronary syndrome and non-valvular atrial fibrillation. METHODS: In the multicenter prospective registry study of the efficacy and safety of a combined antithrombotic therapy 103 patients with non-valvular atrial fibrillation both undergoing or not a percutaneous coronary intervention were enrolled. The trial assessed the primary outcomes (major bleeding, in-hospital death, cardiovascular death, stroke\transient ischaemic attack, death/renal insufficiency) and secondary outcomes (platelet reactivity units (PRU), rivaroxaban concentration). RESULTS: For none of the clinical outcomes when combined with other covariates, the carriership of polymorphisms CYP3A5*3 rs776746, CYP2C19*2 rs4244285;*17 rs12248560, ABCB1 3435 C>T, ABCB1 rs4148738 was significant. None of the markers under study (CYP3A5*3 rs776746, CYP2C19*2 rs4244285, *17 rs12248560, ABCB1 3435 C>T, ABCB1 rs4148738) has proven to affect rivaroxaban equilibrium concentration in blood plasma among patients with atrial fibrillation and acute coronary syndrome. CONCLUSION: In situations of double or triple antithrombotic rivaroxaban and clopidogrel therapy among patients with atrial fibrillation and acute coronary syndrome, the genetic factors associated with bleeding complications risk (CYP2C19*17) may prove to be clinically relevant.
ABSTRACT
Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the pharmaceutical substance and tablet mass. GSB-106 concentrations in the blood plasma were determined by HPLC-mass spectrometry. Relative bioavailability of GSB-106 tablet form was 160.79±24.33%.
Subject(s)
Antidepressive Agents/pharmacokinetics , Dipeptides/pharmacokinetics , Administration, Oral , Animals , Antidepressive Agents/blood , Area Under Curve , Biological Availability , Dipeptides/blood , Drug Evaluation, Preclinical , Male , Rabbits , TabletsABSTRACT
The phase transitions in the rock-salt type SiC (B1-SiC) under decompression are studied in the framework of first-principles molecular dynamics simulations up to room temperature. The transformation pathways were determined based on an analysis of the symmetry and phonon spectra of high-symmetry transient structures identified in the simulations. The plausible pathways of the transformation of B1-SiC into the 3C-, 2H-, 4H-, 12R-SiC polytypes were suggested. The transformation paths were found to depend on both the availability of soft phonon modes in an unreconstructed phase and the initial conditions of the simulation. It is shown that an increase in cell volume at decompression leads to the condensation of a certain phonon mode. As a result, an intermediate state forms due to the atomic displacements and to subsequent strains related to this mode. All the decompressed structures were compressed back under pressure of 120-250 GPa depending on the type of the decompressed phase and simulation temperature that was in the range of 300-1200 K. The suggested scheme of structural identification can be used to determine the transition paths for the structural transformations of other similar structures under pressure.
ABSTRACT
The study of the pharmacokinetics of new drugs and the identification of active metabolites is a necessary step for effective and safe use in the clinical practice. It is especially important for peptide drugs due to their enzymatic instability, low bioavailability and poor permeability through the blood-brain barrier (BBB). The role of endogenous neuropeptides containing cyclic amino acids, proline, pyroglutamic acid, and glycine, in the regulation of memory processes is known as terminal peptide fragments. The development of nootropic drugs based on natural neuropeptides with high pharmacological activity and improved pharmacokinetic properties (enzymatic stability, high bioavailability, and good permeability through the BBB) is an important problem of modern neuropsychopharmacology. Developed drugs - representing short (di- and tri-) peptides appear to meet these requirements. In the Zakusov Research Institute of Pharmacology a nootropic agent noopept (N-phenylacetyl-prolyl-L-glycine ethyl ester), was developed and introduced into medical practice, studies of its pharmacokinetics in ratsrevealed that the noopept metabolite found in the rat plasma and brain, cyclo-prolyl-L-glycine (CPG), differed significantly in its pharmacokinetic parameters from noopept, but at the same time it had similar noopept multi-component spectrum of pharmacological action, namely the influence on higher integrative functions of memory.
Subject(s)
Glycine/metabolism , Animals , Dipeptides , Nootropic Agents , Peptide Fragments , RatsABSTRACT
Metabolism of a novel anxiolytic GML-1 (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-a]pirazin-3-carboxamide) in rat blood plasma was studied by HPLC-mass spectrometry. Three biotransformation products with the corresponding molecular ions were detected. A conclusion was made that the main pathways of GML-1 metabolism are oxidative reactions yielding hydroxylated, methylated, and demethylated metabolites.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Animals , Anti-Anxiety Agents/blood , Biotransformation , Chromatography, High Pressure Liquid , Drug Evaluation, Preclinical , Ligands , Mass Spectrometry , Oxidation-Reduction , Oxygen/chemistry , RatsABSTRACT
Macroporous cryogels containing mixtures of two key components of the dermal extracellular matrix, fibrinogen and collagen-derived gelatin, were evaluated for use as dermal tissue regeneration scaffolds. The infiltration of human dermal fibroblasts into these matrices was quantitatively assessed in vitro using a combination of cell culture and confocal laser scanning microscopy. The extent of cellular infiltration, as measured by the number of cells per distance travelled versus time, was found to be positively correlated with the fibrinogen concentration of the cryogel scaffolds; a known potentiator of cell migration and angiogenesis within regenerating tissue. An analysis of the proteins expressed by infiltrating fibroblasts revealed that the cells that had migrated into the interior portion of the scaffolds expressed predominantly F-actin along their cytoplasmic stress fibres, whereas those present on the periphery of the scaffolds expressed predominantly α-smooth muscle actin, indicative of a nonmotile, myofibroblast phenotype associated with wound contraction. In conclusion, the cryogels produced in this study were found to be biocompatible and, by alteration of the fibrinogen content, could be rendered more amenable to cellular infiltration.
Subject(s)
Cryogels/chemistry , Fibrinogen/chemistry , Gelatin/chemistry , Tissue Scaffolds/chemistry , Acellular Dermis/metabolism , Actins/physiology , Biocompatible Materials , Cell Culture Techniques , Cell Movement , Collagen/chemistry , Cryogels/metabolism , Extracellular Matrix , Humans , Phenotype , Regeneration , Tissue Engineering , Wound HealingABSTRACT
We have studied the pharmacokinetics of drug-marker of cytochrome P450 isoenzyme CYP2C9 (losartan) and its metabolite E-3174 after subchronic oral administration of afobazole in doses 5 and 25 mg/kg in rats. The metabolic ratio (MR) of E-3174/Losartan was calculated. The pharmacokinetic parameters of losartan and its metabolite on the background of 4-day afabazole administration 5 mg/kg dose were not significantly different from analogous values calculated for the control group of rats. Therefore, afobazole in the effective anxiolytic dose did not change the MR value of metabolized P450 isoform. A five-fold dose increase in the afobazole dose led to significant difference in pharmacokinetic parameters, including A UC0-t, Cmax, Kel, t1/2el, MRT, CL/F, and Vd/F of losartan and AUC0-T, Cmax, and Tmax of E-3174. These findings are indicative of the induction of CYP2C9 isoenzyme by afobazole.
Subject(s)
Anti-Anxiety Agents/pharmacology , Benzimidazoles/pharmacology , Cytochrome P-450 CYP2C9 Inducers/pharmacology , Cytochrome P-450 CYP2C9/metabolism , Imidazoles/pharmacokinetics , Losartan/pharmacokinetics , Morpholines/pharmacology , Tetrazoles/pharmacokinetics , Animals , Animals, Outbred Strains , Anti-Anxiety Agents/blood , Area Under Curve , Benzimidazoles/blood , Biotransformation , Cytochrome P-450 CYP2C9 Inducers/blood , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Interactions , Imidazoles/blood , Losartan/blood , Male , Morpholines/blood , Rats , Tetrazoles/bloodABSTRACT
We studied pharmacokinetics of dilept after single cross-administration of tablets and substance of dilept in a dose of 40 mg to rabbits. The following pharmacokinetic parameters were calculated: maximum plasma concentration of dilept, time to maximum observed concentration, area under the pharmacokinetic curve, elimination half-life, and relative bioavailability. Dilept concentration in blood plasma was estimated using ultra-fast liquid chromatography with mass spectrometry detection. Relative bioavailability of dilept tablets was 93.46±28.91% of that for the substance.
Subject(s)
Proline/analogs & derivatives , Tyrosine/analogs & derivatives , Animals , Area Under Curve , Biological Availability , Chromatography, High Pressure Liquid , Half-Life , Models, Statistical , Proline/administration & dosage , Proline/blood , Proline/pharmacokinetics , Rabbits , Tablets , Time Factors , Tyrosine/administration & dosage , Tyrosine/blood , Tyrosine/pharmacokineticsABSTRACT
Interspecies differences in pharmacokinetics of the original neuroleptic drug dilept have been studied in experimental animals (rabbits and rats) and volunteers after single oral administration of tablets and tablet mass of the drug. Parent drug in the rabbit blood plasma was detected for 4 h, in the rat plasma for about 2 h, and in the human blood plasma for about 1 h after drug administration. The degrees of dilept biotransformation into metabolites (defined as metabolism intensity, AUCM/AUCP) in rats were 21.3 (for M-1) and 1645 (for M-2), in human volunteers - 5.8 and 658.5, and in rabbits - 1.6 and 125.8, respectively. Thus, the intensity of drug metabolism in experimental animals and volunteers was different and decreased in the series rats humans rabbits.
Subject(s)
Antipsychotic Agents/administration & dosage , Antipsychotic Agents/pharmacokinetics , Proline/analogs & derivatives , Tyrosine/analogs & derivatives , Adult , Animals , Dose-Response Relationship, Drug , Female , Humans , Male , Proline/administration & dosage , Proline/pharmacokinetics , Rabbits , Rats , Tyrosine/administration & dosage , Tyrosine/pharmacokineticsABSTRACT
The pharmacokinetic study of a new original antipsychotic drug Dilept in healthy volunteers was performed. Volunteers received Dilept as single 20, 40 or 60 mg tablets. The parent drug in the human blood plasma was detected in low concentrations and short-term time due to intensive biotransformation with formation of two metabolites N-caproyl-L-prolyl-tyrosin (M-1) and N-caproyl-L-prolin (M-2). After 20 and 40 mg of Dilept parent drug was detected in certain time points and after 60 mg for 1 h. M-1 and M-2 metabolites were registered in the blood plasma for 4 - 8 h. Theirs concentrations were 10 - 100 times higher of unchanged drug ones. Metabolites pharmacokinetics in the studied dosage range was nonlinear.